Loading...
Teva Pharmaceutical Industries Limited
TEVA•NYSE
Healthcare
Drug Manufacturers - Specialty & Generic
$16.27
$-0.04(-0.21%)
Teva Pharmaceutical Industries Limited (TEVA) Financial Performance & Statements
Review Teva Pharmaceutical Industries Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
4.40%
↑ 4.40%
Operating Income Growth
-169.98%
↓ 169.98%
Net Income Growth
-193.20%
↓ 193.20%
Operating Cash Flow Growth
-8.85%
↓ 8.85%
Operating Margin
7.54%
↑ 7.54%
Gross Margin
49.16%
↑ 49.16%
Net Profit Margin
-7.73%
↓ 7.73%
ROE
-21.36%
↓ 21.36%
ROIC
4.60%
↑ 4.60%
Teva Pharmaceutical Industries Limited (TEVA) Financial Statements
Explore quarterly and annual reports for Teva Pharmaceutical Industries Limited stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $4.23B | $4.33B | $4.16B | $3.82B |
| Cost of Revenue | $2.11B | $2.18B | $2.14B | $2.05B |
| Gross Profit | $2.12B | $2.15B | $2.02B | $1.77B |
| Gross Profit Ratio | $0.50 | $0.50 | $0.49 | $0.46 |
| R&D Expenses | $247.00M | $240.00M | $279.00M | $242.00M |
| SG&A Expenses | $952.00M | $924.00M | $939.00M | $886.00M |
| Operating Expenses | $2.15B | $2.20B | $2.03B | $1.13B |
| Total Costs & Expenses | $4.26B | $4.38B | $4.17B | $3.18B |
| Interest Income | -$48.00M | $0.00 | $0.00 | $0.00 |
| Interest Expense | $239.00M | $272.00M | $241.00M | $250.00M |
| Depreciation & Amortization | $269.00M | $259.00M | $259.00M | $272.00M |
| EBITDA | $261.00M | $207.00M | $254.00M | $55.00M |
| EBITDA Ratio | $0.06 | $0.05 | $0.06 | $0.01 |
| Operating Income | -$29.00M | -$51.00M | -$5.00M | -$218.00M |
| Operating Income Ratio | -$0.007 | -$0.01 | -$0.001 | -$0.06 |
| Other Income/Expenses (Net) | -$218.00M | -$273.00M | -$240.00M | -$253.00M |
| Income Before Tax | -$247.00M | -$324.00M | -$245.00M | -$467.00M |
| Income Before Tax Ratio | -$0.06 | -$0.07 | -$0.06 | -$0.12 |
| Income Tax Expense | $28.00M | $69.00M | $630.00M | -$52.00M |
| Net Income | -$217.00M | -$437.00M | -$846.00M | -$139.00M |
| Net Income Ratio | -$0.05 | -$0.10 | -$0.20 | -$0.04 |
| EPS | -$0.19 | -$0.39 | -$0.75 | -$0.12 |
| Diluted EPS | -$0.19 | -$0.39 | -$0.75 | -$0.12 |
| Weighted Avg Shares Outstanding | $1.13B | $1.13B | $1.13B | $1.12B |
| Weighted Avg Shares Outstanding (Diluted) | $1.13B | $1.13B | $1.13B | $1.12B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan